James Healy - Jan 6, 2022 Form 3 Insider Report for CinCor Pharma, Inc. (CINC)

Role
Director, 10%+ Owner
Signature
/s/ Cathy Rude, Attorney-in-Fact
Stock symbol
CINC
Transactions as of
Jan 6, 2022
Transactions value $
$0
Form type
3
Date filed
1/6/2022, 07:53 PM
Previous filing
Sep 29, 2021
Next filing
Feb 11, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CINC Series A Preferred Stock Jan 6, 2022 Common Stock 3.99M By Sofinnova Venture Partners X, L.P. F1, F2
holding CINC Series B Preferred Stock Jan 6, 2022 Common Stock 1.26M By Sofinnova Venture Partners X, L.P. F1, F2
holding CINC Stock Option (Right to Buy) Jan 6, 2022 Common Stock 29.4K $13.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock and Series B Preferred Stock will automatically convert into shares of Common Stock on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
F2 The shares are directly held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. The Reporting Person is a managing member of SM X and may be deemed to share voting and dispositive power over the shares held by SVP X. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.
F3 This option vests in equal annual installments over a three-year period measured from one year following December 10, 2021, subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney